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Women in substance abuse programs have high rates of smoking. Pregnancy represents a unique opportunity for intervention,
but few data exist to guide tailoring of eﬀective interventions. In this study, 44 pregnant and 47 nonpregnant opioid-dependent
women enrolled in comprehensive substance abuse treatment received a 6-week smoking cessation intervention based on the 5A’s
counseling model. The number of daily cigarettes decreased by 49% for pregnant patients and 32% for nonpregnant patients at the
3-month followup. Length of time in substance abuse treatment did not correlate with smoking cessation or reduction for either
group. Factors predicting reduction of cigarette smoking diﬀered for pregnant versus nonpregnant patients. For pregnant patients,
lower levels of nicotine use prior to intervention and self-reported cigarette cravings predicted successful reduction in smoking.
For nonpregnant patients, lower aﬃliative attachment to cigarettes, reliance on cigarettes for cognitive enhancement, and greater
sense of control predicted more successful outcomes.
1. Introduction
Tobacco use represents a significant long-term risk to
women’s health [1, 2], and cigarette smoking is currently
one of the leading preventable causes of poor pregnancy
outcomes, as well as infant mortality and morbidity [3].
Smoking during pregnancy is associated with increased
risk of preterm birth [4–6], placental abruption, placenta
previa, low birth weight [6–8], and sudden infant death
syndrome (SIDS) [9, 10]. The risks related to cigarette
smoking continue following birth with child exposure to
second hand tobacco smoke associated with an increased
incidence of respiratory ailments such as asthma, respiratory
infections, and bronchiolitis [11–13].
Estimates of the prevalence of smoking in participants
in methadone maintenance programs range from 85 to
98% [14–17]. However, few substance abuse treatment pro-
grams oﬀer smoking cessation interventions, and smoking
cessation is often viewed as a low priority by treatment
program staﬀ [18]. Treatment staﬀ may perceive substance-
dependent individuals as possessing low motivation for
smoking cessation [19] or believe that engaging in eﬀorts
to reduce nicotine dependence may be overwhelming for
substance-dependent individuals, particularly those early in
their recovery [18]. Some studies have also suggested that
methadone maintenance may compound diﬃculty quitting
smoking with a dose-dependent eﬀect on tobacco craving
and nicotine withdrawal symptoms [20, 21] aﬀected through
increased rate of nicotine metabolism or alteration to the
sensitivity of nicotine receptors [22]. The reinforcing eﬀects
of nicotine, such as enhancement of cognitive performance,
may also be stronger in methadone-maintained individuals
[23].
Fortunately, pregnancy often represents a uniquemotiva-
tion for smoking cessation among women who use nicotine
[24], and substance-dependent individuals frequently self-
report a desire to quit smoking [25]. However, eﬀorts to
encourage smoking cessation in methadone maintenance
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programs have had limited success, with reduction in smok-
ing appearing to be a more realistic goal than cessation
[26]. Recently it has been suggested that smoking cessation
interventions for pregnant womenmay need to be tailored to
their specific needs, similar to intervention for dependence
or abuse of other substances [27]. However, little data exist
to suggest what factors are associated with eﬀectiveness of
smoking cessation interventions in pregnant women, or how
these may diﬀer from nonpregnant women in substance
abuse treatment programs.
This study compares outcomes of a 6-week smok-
ing cessation intervention for pregnant and nonpregnant
methadone-maintained women enrolled in a comprehensive
outpatient substance abuse treatment program. The eﬀec-
tiveness of the intervention is compared between the two
groups, and factors associated with successfully reducing
or eliminating cigarette use in pregnant and nonpregnant
women are examined.
2. Methods
2.1. Participants. Participants were 44 opioid-dependent
pregnant women and 47 opioid-dependent parenting
women receiving comprehensive outpatient substance abuse
treatment. Patients who were identified by their primary
counselors as nicotine dependent were referred for a six-
week group smoking cessation intervention based on the 5
A’s counseling model [28]. The 5 A’s counseling approach
is a five-step intervention that has been proven eﬀective for
use with pregnant women and is consistent with strategies
developed by the National Cancer Institute and American
Medical Association [29]. The steps include: asking about
tobacco use; advising to quit; assessing patient motivation
to quit; assisting in quit attempt; arranging for followup.
Group content included assessment of current nicotine use,
education on risks of tobacco use and benefits of cessation,
identification of patient motivations to quit and triggers to
smoke, and coping skills. Groups ran from April 2009 to
March 2010 and included 8–15 patients per group.
2.2. Procedures. The Timeline Follow Back (TLFB) was
administered during the week prior to the intervention. At
the initial administration, pregnant participants were asked
to report on their cigarette use from one month prior to
pregnancy to the present. Parenting patients were asked to
report on their cigarette use for one month prior to the
intervention. The TLFB was administered again at the group
intervention’s midpoint (3 weeks), at the conclusion of the
six-week group, and then once monthly for three months
postintervention. An anonymous 10-item group evaluation
was also administered at the close of the six-week group.
The evaluation assessed patient knowledge of the risks of
tobacco use, skills for managing cravings, and satisfaction
with the content and format of the group. The Wisconsin
Inventory of Smoking Dependence Motives (WISDM) was
also administered to all patient one week prior to the
intervention and again at the 3-month followup.
2.3. Measures
2.3.1. Timeline Follow Back (TLFB). The TLFB is a calendar
format measure that utilizes memory aids such as important
dates and events to aid recall of substance use over a specified
period of up to 12 months. It has been used for over thirty
years in clinical and research settings [30].
2.3.2. Wisconsin Inventory of Smoking Dependence Motives
(WISDM). The WISDM is a 68-item measure of smok-
ing dependence to assess the underlying motivations for
smoking [31]. It is based on the theory that multiple
motives for tobacco use comprise the construct of tobacco
dependence, not solely nicotine dependence. These motives
may contribute to tobacco use, withdrawal, and relapse.
It has 13 subscales with internal consistency estimates
ranging from 0.78 to 0.89 [32]. Subscales are Aﬃliative
Attachment, Automaticity, Behavioral Choice-Melioration,
Cognitive Enhancement, Craving, Cue Exposure, Loss of
Control, Negative Reinforcement, Positive Reinforcement,
Social-Environmental Goads, Taste and Sensory Properties,
Tolerance, andWeight Control. Participants are asked to rate
each of the 68 items on a scale of 1–7 with 1 being “not at all
true of me” and 7 being “extremely true of me”.
2.3.3. Group Evaluation. A ten-item anonymous question-
naire assessed increase in patient knowledge regarding risks
of cigarette smoking, benefits of cessation, and response to
cravings; perceived support for smoking cessation; readiness
to change; satisfaction with group format and facilitator.
Participants used a 5-point Likert scale to respond to items
such as “I learned ways to control my cravings for cigarettes”,
“The program taught me things I did know before about
smoking”, and “I believe I am given the support I need to
refrain from smoking”.
2.4. Data Analysis. Descriptive statistics were obtained for
all variables initially included in the model. t-tests were
conducted for key variables (age at entry to substance abuse
treatment, length of time in substance abuse treatment,
number of daily cigarettes at the beginning of intervention,
percent decrease in smoking reporting in months prior to
intervention) to determine if significant diﬀerences existed
between the pregnant and nonpregnant groups prior to
intervention.
Four analyses were conducted utilizing multiple ordinary
least squares regression. Outcome variables were the percent
change in number of cigarettes smoked from beginning of
the intervention to one month postintervention (PC1), and
three months postintervention (PC3), for both the pregnant
and nonpregnant groups. Stepwise regression was conducted
to select variables for the final models. Initial predictor
variables included maternal age, methadone dose, time in
substance abuse treatment at start of the smoking cessation
intervention (TimeTx), average number of cigarettes smoked
daily prior to intervention (Cig Prior), percent change in
number of cigarettes smoked daily from one month prior
to intervention to week 1 of intervention (PC Base-Wk1),
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Table 1: Descriptive statistics total sample.
Pregnant Nonpregnant
P
Mean/percent (SD) Mean/percent (SD)
Maternal age 26.7 (5.0) 27.8 (6.0) 0.9
Race/ethnicity
Caucasian 97.7% 87.5%
African-American 2.3% 10.4%
Latina 0% 2.1%
Time in treatment (wks) 35.1 (5.6) 192.0 (22.7) 0.0001
Methadone dose (mgs) 143.6 (48.6) 128.7 (67.5) 0.2
Table 2: Average number of daily cigarettes by time point.
Time
Pregnant Nonpregnant
Mean (SD) Mean (SD) P
Prior to intervention 18.8 (10.1) 13.2 (1.0) 0.003
Week 1 intervention 15.2 (13.8) 12.4 (1.1) 0.2
Week 6 (end intervention) 8.3 (6.5) 9.3 (5.6) 0.4
1-month followup 8.3 (5.9) 8.6 (5.9) 0.8
3-month followup 7.9 (7.5) 8.5 (6.4) 0.7
number of daily cigarettes smoked at week 1 of the inter-
vention (Cigs Wk1), urine drug analysis positive for illicit
or nonprescribed substances during the 6-week smoking
intervention, satisfaction with the intervention as measured
by total scores on the group evaluation (Satisfaction), and
the 13 subscales of the WISDM. Six variables (PC base-Wk1,
Cigs Wk1, Satisfaction, and three subscales of the WISDM:
Loss of Control, Craving, Automaticity) were retained in the
two models for pregnant patients, and five variables (five
subscales of the WISDM: Aﬃliative Attachment, Cognitive
Enhancement, Taste and Sensory Properties, Loss of Control,
Automaticity) were retained in the two models for the
nonpregnant women.
A multiple analysis of variance (MANOVA) was con-
ducted to determine between group diﬀerences for pregnant
versus nonpregnant patients on three variables: percent
change in cigarette smoking from beginning of the inter-
vention to the one-month followup (PC1), percent change
from beginning of the intervention to the 3-month followup
(PC3), and group satisfaction (Satisfaction).
3. Results
Descriptive statistics for pregnant and nonpregnant patients
are presented in Table 1. No significant diﬀerences existed
between the two groups on maternal age (26.7 yrs versus
27.8 yrs; P = 0.9) or methadone dose (143.6mg versus
128.7mg; P = 0.2). The overall sample was predominantly
Caucasian, with a higher percentage of African-American
and Latina patients in the nonpregnant group (Table 1).
Length of time in substance abuse treatment (Time Tx) was
significantly longer for the nonpregnant patients (35.1 wks
versus 192.0 wks; P = 0.0001) (Table 1).
Table 3: Correlates of decrease in smoking at followup: pregnant
patients.
1-month 3-month
b t P b t P
PC Base-Wk 1 −0.12 −2.68 0.01 −2.52 −1.39 0.17
Cigs Wk 1 −1.33 −3.50 0.001 −2.26 −1.73 0.09
Satisfaction −12.60 −2.03 0.05 −69.35 −2.19 0.04
Automaticity −1.29 −1.87 0.07 −1.26 −0.56 0.58
Craving −2.13 −2.22 0.03 −2.53 −0.81 0.43
Loss of control −1.61 −1.85 0.07 −1.34 −0.48 0.64
∗
PC Base-Wk1: percent change in daily cigarettes prior to intervention;
Cigs Wk1: mean daily cigarettes at start of intervention; Satisfaction:
satisfaction with intervention; WISDM subscales: Automaticity, Craving,
Loss of control.
Pregnant patients reported a significantly higher number
of daily cigarettes prior to the intervention (18.8 versus 13.2;
P = 0.003) (Table 2). However, no significance between
group diﬀerences was found in number of cigarettes smoked
at week 1 of the intervention, suggesting that pregnant
women significantly decreased their rates of smoking prior
to intervention. Mean number of daily cigarettes reported
was not statistically significant between the pregnant and
nonpregnant groups at the end (week 6) of the intervention,
or at the 1-month or 3-month followups. However, mean
number of cigarettes decreased over time for both groups and
continued to decline during the 3-month postintervention
followup (Table 2). Average number of daily cigarettes for
the pregnant group decreased by 49% from week 1 of the
intervention to the 3-month followup. For nonpregnant
patients, mean number of daily cigarettes decreased by 32%.
3.1. Multivariate Regression. Following model selection uti-
lizing stepwise regression, six variables were retained in the
model to predict outcomes at the 1-month and 3-month
followups for pregnant women. A greater percent decrease
in number of daily cigarettes smoked prior the start of the
intervention (PC Base-Wk1) (b = −0.12; P = 0.01), as
well as a higher number of daily cigarettes reported at the
beginning of the intervention (Cigs Wk1) (b = −1.33;
P = 0.001) were both associated with smaller decreases in
number of cigarettes at the 1-month followup for pregnant
patients (Table 3). Greater patient satisfaction with the
intervention correlated with smaller decreases in number of
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cigarettes (b = −12.6; P = 0.05). Higher scores on the
WISDM subscale craving were also associated with a smaller
decrease in cigarette smoking at the 1-month followup (b =
−2.13; P = 0.03) with subscales Automaticity and Loss of
Control showing trends toward significance (Table 3). Only
patient satisfaction with the intervention predicted number
of daily cigarettes at the 3-month followup (b = −69.35;
P = 0.04).
For the nonpregnant patients, five subscales of the
WISDM were retained in the model to predict 1-month and
3-month outcomes. Only the Aﬃliative Attachment (b =
−1.21; P = 0.02) and Cognitive Enhancement (b = −1.67;
P = 0.003) predicted percent change in daily cigarettes at
the 1-month followup (PC1), with higher scores on these
WISDM subscales correlating with smaller PC1 (Table 4).
The Taste and Sensory Properties subscale also showed a
trend toward significance (b = −1.09; P = 0.06). Loss
of Control and Automaticity were not significant in the
final model predicting outcomes at the 1-month followup.
Cognitive Enhancement remained a significant predictor for
percent change in daily cigarettes for nonpregnant patients
at the 3-month followup (PC3) (b = −2.17; P = 0.01).
Higher scores on the Loss of Control subscale also predicted
smaller decreases in PC3 (b = −2.02; P = 0.05). Aﬃliative
Attachment, Taste and Sensory Properties, and Automaticity
subscales all showed trends toward a negative impact on PC3,
but none reached significance at the 0.05 level (Table 4).
3.2. MANOVA. MANOVA results indicate that there were no
significant diﬀerences between pregnant and nonpregnant
groups on the percent decrease in number of daily cigarettes
from baseline at the 1-month (PC1) ( f = 0.18; P =
0.67) or 3-month followups (PC3) ( f = 0.03; P = 0.87).
No significant diﬀerences were found between groups on
satisfaction with the intervention ( f = 1.46; P = 0.21).
4. Conclusions
While only a small percentage of patients in either the
pregnant or nonpregnant groups ceased nicotine use entirely,
reductions in number of cigarettes smoked daily were
substantial for many patients, and these reductions were
maintained, or even increased, over time. The number
of people who quit smoking entirely increased from the
end of the intervention to the 3-month followup, and the
mean number of daily cigarettes decreased following the
intervention for both groups as well, suggesting that it may
take time to integrate new information and implement the
coping skills learned in the group.
No significant diﬀerences were found in the number of
cigarettes smoked at the 1-month or 3-month followups, or
in the percent decrease of daily cigarettes from the begin-
ning of the intervention to the followups between groups,
suggesting that the intervention was equally eﬃcacious for
both pregnant and nonpregnant women. However, pregnant
patients reported a greater self-imposed decrease in cigarette
smoking leading up to the intervention. While both the
pregnant and nonpregnant patient groups were similar in
demographics and level of nicotine dependence prior to
Table 4: Correlates of decrease in smoking at followup: nonpreg-
nant patients.
1-month 3-month
b t P b t P
Aﬃliative
attachment
−1.21 −2.49 0.02 −1.42 −1.91 0.06
Cognitive
enhancement
−1.67 −3.10 0.003 −2.17 −2.61 0.01
Taste and
sensory
properties
−1.09 −1.93 0.06 −1.53 −1.83 0.08
Automaticity −0.66 −1.15 0.26 −1.51 −1.77 0.09
Loss of control −0.98 −1.24 0.22 −2.20 −2.02 0.05
∗
WISDM subscales: Aﬃliative attachment, Cognitive enhancement, Taste
and sensory properties, Automaticity, Loss of control.
the intervention, the pregnant patients had also been in
substance abuse treatment significantly fewer weeks than
nonpregnant patients. This is expected since the discovery of
pregnancy is a common motivator for entry into substance
abuse treatment. The decrease in cigarette smoking prior to
intervention may represent the eﬀects of entry into substance
abuse treatment, or the motivation of discovery of pregnancy
on nicotine use behaviors.
Although outcomes were similar for pregnant and
non-pregnant patients, diﬀerent factors predicted success-
ful outcomes for the two groups. Number of cigarettes
smoked daily at the start of the intervention, as well as
the decrease the individual was able to aﬀect prior to
intervention influenced outcomes for pregnant women. This
is consistent with previous literature suggesting that the
heavier nicotine use correlates with less successful outcomes
in smoking cessation eﬀorts [33, 34]. However, for pregnant
women, level of craving for cigarettes appeared to be a
significant factor, whereas for nonpregnant women, the
aﬃliative attachment to cigarettes and their role in cognitive
enhancement appeared to be more central. Perhaps the most
puzzling finding is that those pregnant women who were
more satisfied with the intervention demonstrated smaller
decreases in smoking at followup. It is possible that these
women represented patients in the precontemplation stage
who appreciated receiving the information contained in the
intervention but were not ready to commit to cessation of
nicotine use.
Limitations. Conclusions are limited by reliance on self-
report data, which is subject to recall bias and socially
desirable responding. Patients may underestimate, inaccu-
rately recall, or wish to downplay the number of cigarettes
smoked, particularly pregnant patients. Further research on
the eﬀectiveness of smoking cessation interventions may
benefit from use of additional biological measure, such as
cotinine testing, to evaluate reports of reductions in or
cessation of nicotine use.
This study is also limited by small sample size. Lack of
power may have obscured relationships which would have
reached significance had the n been greater. In particular,
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subscales of the WISDM showed trends towards predicting
decreases in number of daily cigarettes at the 1-month and
3-month followups but did not reach significance in the final
models.
Implications for Clinical Practice. This study provides evi-
dence that substantial reductions in cigarette smoking are
possible for methadone-maintained patients, even following
a relatively brief intervention. It also suggests that smoking
cessation interventions may be eﬀective even for patients that
are relatively early in their recovery from substance abuse.
However, as it appears that reductions occurred over time
and required integration of the new skills, longer smoking
cessation interventions or follow-up support may be useful
in maintaining or increasing gains over time.
Results also indicate that the factors associated with
success of smoking cessation interventions may diﬀer for
pregnant versus nonpregnant women. For pregnant women,
pregnancy represents a unique motivation to decrease their
nicotine use, and many pregnant patients appear to have
begun this process prior to intervention and were able
to further decrease their use following intervention. Heav-
ier smoking as well as greater self-imposed decrease in
cigarette smoking prior to intervention appeared to lessen
the eﬀectiveness of the intervention for pregnant women,
consistent with previous literature. Higher scores on the
craving subscale of the WISDM suggest that for pregnant
women, particularly those who are newer to substance abuse
treatment, increased focus on the management of cravings
may be especially helpful. Further research is needed on
eﬃcacious treatment for nicotine dependence in this special
population; however, this study does provide evidence that
smoking cessation interventions are a worthwhile endeavor
for women in substance abuse treatment programs.
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